Mecobalamin

Overview

Not Available

Indication

Not Available

Associated Conditions

Vitamin B12 Deficiency

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling	2025/02/06	NCT06813274	Phase 2	Not yet recruiting	Hejiang Ye
Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury	2024/01/24	NCT06220929	Phase 4	Not yet recruiting	Sichuan Provincial People's Hospital
Effect of Ultrasound-guided Stellate Ganglion Block Combined With Facial Nerve and Glossopharyngeal Nerve Block on the Treatment of Sudden Deafness	2022/11/21	NCT05623384	Not Applicable	Recruiting	Zhuan Zhang
Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients	2022/01/11	NCT05184049	Phase 4	UNKNOWN	Xiangya Hospital of Central South University
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome	2021/12/21	NCT05165069	Phase 3	Active, not recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia	2021/08/17	NCT05008042	Phase 1	Completed	Linnaeus University
Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis	2021/03/16	NCT04800666	Not Applicable	Completed	Zhuan Zhang
A Randomized Controlled Trial of Mecobalamin Injection and Tablet Treatment Efficacy on Mild to Moderate Diabetic Peripheral Neuropathy	2020/05/04	NCT04372316	Phase 2	UNKNOWN	Peking University Third Hospital
Effect of Rotating Magnetic Therapy on Diabetic Peripheral Neuropathy	2019/06/12	NCT03983200	Not Applicable	UNKNOWN	Majianhua
Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients	2018/07/20	NCT03593304	Phase 2	Completed	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
MIC B12	Perdido Key Health and Wellness Inc	70104-806	INTRAMUSCULAR	1 mg in 1 mL	11/23/2015
Methaver	Sterling-knight Pharmaceuticals,LLC	69336-353	ORAL	2 mg in 1 1	11/24/2015
Zyrexal	Vivera Pharmaceuticals, Inc.	72380-915	ORAL	1 mg in 1 1	2/10/2020
Vita-Rx Diabetic Vitamin	MAS Management Group Inc.	69677-050	ORAL	0.0025 mg in 1 1	8/11/2015
Vita-Rx Diabetic Vitamin	Pure Source, LLC	65121-301	ORAL	0.0025 mg in 1 1	11/22/2023
Livita Children	PureTek Corporation	59088-660	ORAL	0.8 ug in 1 mL	12/18/2023
Multivitamin	PureTek Corporation	59088-018	ORAL	4.5 ug in 1 1	5/15/2025
B-Combo	Perdido Key Health and Wellness Inc	70104-110	INTRAMUSCULAR	1 mg in 1 mL	11/23/2015
Lipovite	Perdido Key Health and Wellness Inc	70104-128	INTRAMUSCULAR	1 mg in 1 mL	11/23/2015
Davimet-M	PureTek Corporation	59088-158	ORAL	4.5 ug in 1 1	11/30/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
METHYCOBAL INJECTION 500 mcg/ml	Nipro Pharma Corporation Ise Plant	SIN06349P	INJECTION	500 mcg/ml	7/3/1991
METHYCOBAL TABLET 500 mcg	BUSHU PHARMACEUTICALS LTD.	SIN06291P	TABLET, SUGAR COATED	500 mcg	6/20/1991
MECONEURO CAPSULES 500 MCG	PT. Novell Pharmaceutical Laboratories	SIN16735P	CAPSULE	500 mcg	3/8/2023
NEUROMETHYN CAP. 500 mcg	SAM CHUN DANG PHARM CO LTD	SIN10917P	CAPSULE	500 mcg	5/5/1999

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
MEDBALCO TABLETS 500MCG	N/A	VICKMANS LABORATORIES LIMITED	N/A	N/A	8/20/2024
METHYCOBAL INJECTION 500 MCG/ML	N/A	EISAI (HONG KONG) COMPANY LIMITED	N/A	N/A	8/15/2016
METHYCOBAL TAB 500UG	N/A	EISAI (HONG KONG) COMPANY LIMITED	N/A	N/A	9/6/1988

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
Energy Multi	453128	Australian Pharmaceutical Industries Pty Ltd	Medicine	A	6/21/2024
NanoCelle Activated B12	329112	Natural Bio Pty Limited	Medicine	A	1/23/2020
Kids Multi	329564	Factors Group Australia Pty Ltd	Medicine	A	2/6/2020
METAGENICS ENERGYX TROPICAL FLAVOUR	343670	Metagenics (Aust) Pty Ltd	Medicine	A	9/17/2020
InNatal	346421	FIT-BioCeuticals Pty Ltd	Medicine	A	10/22/2020
NutriVital Methyl B12 2500 mcg	279823	Nutrivital Pty Ltd	Medicine	A	9/1/2016
METAGENICS FIBROPLEX PLUS ORANGE	350478	Metagenics (Aust) Pty Ltd	Medicine	A	12/2/2020
Hydra Longevity Cellular Energy	444673	Hydra Longevity Operations Pty Ltd	Medicine	A	3/27/2024
Metabolism & Energy Superblend	397843	Goddess Health Company Pty Ltd	Medicine	A	10/17/2022
METAGENICS HPA ESSENTIALS	445132	Metagenics (Aust) Pty Ltd	Medicine	A	4/3/2024

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Eisai's Rozebalamin (Mecobalamin) Launched in Japan for Amyotrophic Lateral Sclerosis

9 months ago

Eisai's Rozebalamin for Injection 25mg (mecobalamin) has been launched in Japan to slow the progression of functional impairment in amyotrophic lateral sclerosis (ALS).

New Drug Development Pipeline Shows Promise for ALS Treatment with 53 Candidates Under Investigation

3 years ago

A comprehensive review of ALS drug development reveals 53 new drug candidates in clinical trials between 2020-2022, with 13 compounds advancing to Phase 3 trials and showing promising therapeutic potential.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access